Innate Pharma Presents IPH6501 Preclinical Data At EHA 2025, Highlighting Potential In Relapsed, Refractory, And Untreated CD20+ B-NHL
Benzinga Newsdesk 1 year ago
News
Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular
- Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented
- Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL patients
- IPH6501 is currently under investigation in a Phase 1/2 clinical study in relapsed and/or refractory (R/R) CD20+ B-cell non-Hodgkin lymphoma